Of 2005, imported to the U.S. Senate in April 2005, a request for transferable rights so called at the mental contains transferable rights at the mental property the project BioShield II act property, in which an enterprise, which developed, would reach a vaccine for an illness such as AIDS a Wildcardpatentverlängerung, which could be used at a drug of its choice in the United States. The request received the label international AIDS of the Vaccine initiative, which sees each possible request, in order to positively increase research into AIDS vaccines. Therefore this is a request, which earns serious exact investigation. There are at least three very important errors in the fundamental mechanism, which is suggested of Project BioShield II (and transferable rights at the mental property generally. First the way, which is financed the reward for the pioneer by a patent extension, is ineffective and inadequate. Secondly the spurring mechanism is defined badly and free method teachings does not offer, in order to determine like one largely a reward, for a given innovation pays. Thirdly the mechanism separates against small enterprises. First you regard then the way that financing for this mechanism is raised. Transferable rights at the mental property essentially offer away of the supply way dbücher payment to the companies, which develop somewhat socially desirable innovation, like a vaccine for HIV/AIDS. On innovation at present ignoring the effect, you regard, how this payment will receive. The pioneer is rewardedwith awildcard patent expansion of says we two year to 88 Aidan Hollis on any without reference product. E.G. you assume that Pfizer developed an AIDS vaccine; under BioShield II it would reach a Wildcardpatentverlängerung, which could use it at Lipitor. But this is equivalent with a situation functionally, in which the government to patent decline waited, and hunted a heavy tax generically produced versions of Lipitor for two years up, if Pfizer the tax revenues are paid, as reward for its AIDS vaccine innovation. Like that transferable rights at the mental property would be actually simply a very specific tax, which was imposed upon to consumers one without reference product. Normally specific taxes of this kind it is there issomereason todiscourage consumption of the product avoided (like the case with cigarette and alcohol taxes). Instead governments in developed countries bend, with a broad basis taxes to use out this spreading the load of the taxation. With a broad basis taxes appeal for two reasons. First they bend to cause less distortion in buying decisions than product specific taxes which raise the same gross incomes. Secondly taxes are fair with a broad basis, since they impose the load of the taxation of a large selection of the people. A decision to use to the one product specific tax if neither the quantity of the tax nor the product, to which it is imposed upon, are determined of the government, must be completely ad hoc obvious. Thiswould is approximately equivalent with a government policy of imposing the very high taxes different products at randomto the building of capital STR eating. Infact, is it evenworse, since the expansion of the tax falls on people, which are usually ill (and therefore using any without reference drug). To understand is hard, of a badly sketched systemfor financing innovation as this. The second general problem with transferable rights at the mental property is the fact that it of exact know no way gives, how much an innovation is requested in order the reward of a patent extension to receive. Was a vaccine for malaria the same opportunity for a transferable patent extension received as drug, which treats Chagas illness? What, if only were a little effective? Each possible authorization, which would like to offer such a reward, would have to specify something over criteria for the reward in advance. The project BioShield II act (P. 301 (B) (4) (A) (II)) it shows that the suitability for a patent extension is carefully weighed, with the length of the extension-dependent in the part on the difficulty of the innovation, usefulness of alternatives, seriousness of the threat and effect of the patent extension on consumers on. That is, it uses an indefinite measure of the therapeutic importance of the innovation, weighed out against any indefinite measure of commercial meaning of the patent extension to determine the reward to be as large should. This is not essentially a kind of the connectionless alternatively released reward system, if the measures are very badly accomplished, anything, which is obviously in advance specified, and immeasurable discretion of sides of the administrator.8 and since that administratorSince, which is relatively new the alternatively released reward request, it, has, to confront serious exact investigation of a broad public. When such remains it an interesting idea, which can earn further analysis and view. There of acres RK leases three very important flaws into the basic mechanism proposed by Project BioShield II (and Transferable Intellectual Property Rights in general). Roofridge, the way the reward for the innovator is financed through A patent extension is inefficient and inequitable. Second, the incentive mechanism is poorly defined, and of does emergency of offer A CLEARs methodology ton determine how large A reward tons pay for A given innovation. Third, the mechanism discriminates against small firms. Roofridge, then, more consider the way that financing is raised for this mechanism. Essentially, Transferable Intellectual Property Rights more offer away OF providing on off the books financial reward tons of companies that develop some socially desirable innovation, look for as A vaccine for HIV/AIDS. Ignoring the effect on innovation for the moment, more consider how this financial reward is obtained. The innovator is rewardedwith awildcard patent extension OF, say, two years 88 Aidan Hollis on some unrelated product. For example, suppose Pfizer developed at AIDS vaccine; under BioShield II it would obtain A wildcard patent extension that it could apply tons of Lipitor. But this is functionally equivalent tons of A situation into which the government waited until patent expiration, and imposed A heavy tax on generically produced version OF Lipitor for two years, with the tax revenues paid ton Pfizer as A reward for its AIDS vaccine innovation. Thus, Transferable Intellectual Property Rights would in fact simply fuel element A very specific tax imposed on consumers OF unrelated product on. Normally, specific taxes OF this sort acres avoided unless there issomereason todiscourage consumption OF the product (as is the case with cigarette and Alco-get taxes). Instead, governments into developed countries tend ton use broad based taxes that spread out the burden OF rating. Broad based taxes of acres appealing for two reasons. Roofridge, they tend ton create less distortion into buying decisions than product specific taxes that raise the same of totally revenues. Second, broad based taxes of acres equitable since they impose the burden OF rating on A wide rank OF people. A decision ton use A product specific tax, when more neither the amount OF the tax nor the product on which it is imposed is determined by the government, must obviously fuel element completely ad hoc. Thiswould fuel element roughly equivalent tons of A government policy OF imposing very high taxes on various products RK randomto find road construction. Infact, it is evenworse, since the incidence OF the tax if on people who acres, typically, crimps (and hence using some unrelated drug). It is hard ton conceive OF A more poorly designed systemfor funding innovation than this. The second general problem with Transferable Intellectual Property Rights is that there is NO way OF knowing exactly how much OF at innovation is required tons obtain the reward OF A patent extension. Would A vaccine for malaria GET the same opportunity for A transferable patent extension as A drug treating Chagas disease? What if it were only somewhat effective? Any authority wishing tons more offer look for A reward would need tons specify something about criteria for the reward into advance. The Project BioShield II act (P. 301 (b) (4) (A) (ii)) indicates the eligibility for A patent extension wants fuel element that carefully weighed, with the length OF the extension dependent difficulty OF innovation, availability OF alternative, in part on, seriousness OF the threat, and impact OF the patent extension on consumers. In more other words, it is using on undefined measure OF therapeutic importance OF the innovation, balanced some undefined measure OF commercial significance OF the patent against extension, ton determine how large the reward should fuel element. Into essence, this is A sort OF incoherent optionally Reward system, with measurements very poorly performed, emergency-hung clearly specified into advance, and immense discretion on the part OF the administrator.8 and since the administratorSince the optionally Reward proposal is relatively recent, it has yet ton face serious scrutiny from A wide audience. As look for, it remains on interesting idea that May deserve analysis and consideration.